SFU
ALNY icon

Stonehage Fleming (UK)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stonehage Fleming (UK)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-308
Closed -$30K – 196
2014
Q4 		$30K Sell
308
-128
-29% -$11.9K 0.01% 216
2014
Q3 		$34K Sell
436
-26
-6% -$1.68K 0.02% 204
2014
Q2 		$29K Sell
462
-965
-68% -$57.4K 0.01% 214
2014
Q1 		$96K Buy
1,427
+236
+20% +$18.3K 0.04% 178
2013
Q4 		$77K Buy
+1,191
New +$71K 0.03% 179

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stonehage Fleming (UK)'s ALNY Position: Q1 2015 in Review

Stonehage Fleming (UK) sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2015, closing a stake of 308 shares — an estimated $30K sold.

Stonehage Fleming (UK) first reported a position in ALNY in Q4 2013 and held it in 5 quarters. The position peaked at $96K in Q1 2014. 238 funds tracked by Wall St. Rank hold ALNY as of Q1 2015.

  • Stonehage Fleming (UK) reported no remaining Alnylam Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 308 Alnylam Pharmaceuticals shares in Q1 2015, an estimated $30K.
  • Stonehage Fleming (UK) first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Stonehage Fleming (UK)'s Alnylam Pharmaceuticals position peaked at $96K in Q1 2014.
  • 238 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2015.

Based on Stonehage Fleming (UK)'s 13F filing for Q1 2015, filed 11 Oct 2019.